Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Prograf

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Prograf was produced by Astellas.

Astellas: Ten years young

Astellas: Ten years young

diff. Alongside these launches the company has been moving into the oncology arena, adding to its legacy interest in urology from Yamanouchi and Fujisawa, and transplantation, where it has Prograf (tacrolimus)

Research units to close as Astellas restructures

Research units to close as Astellas restructures For fiscal 2012, revenues grew a little under 4 per cent to 1, 000bn yen - driven by immunosupressant Prograf (tacrolimus), Vesicare (solifenacin succinate) for overactive bladder and recently-launched prostate cancer

The Re-Launch of ADVAGRAF

Astellas Transplant in association with Kane &Finkel Healthcare. ADVAGRAF launched in the EU in 2007 as the convenient, once-daily formulation of the cornerstone immunosuppressant PROGRAF. ... To build on and secure a dominant position in the market,

Lupus – a 'great imitator'

Immunosuppressants such as mycophenolate mofetil (CellCept, Roche) and tacrolimus (Prograf, Astellas Pharma) are used to inhibit the body's production of auto-antibodies, which are responsible for the classical symptoms of

Astellas files patent suit against Sandoz

Prograf is currently approved in Canada and elsewhere as an immunosuppressant following organ transplantation. ... Sandoz previously launched a generic version of Prograf in the US August 2009.

1 2 3 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics